TWST Earnings: Twist Bioscience Beats Revenue, Misses EPS

Twist Bioscience Corporation (TWST) delivered mixed results in its latest earnings report on May 4, 2026. The synthetic biology company beat revenue expectations but disappointed on the earnings front. Revenue came in at $110.72 million, exceeding the $107.64 million estimate by 2.85%. However, earnings per share fell to -$0.71, missing the -$0.49 estimate by 44.90%. The stock reacted negatively, dropping 6.97% to $56.19 in trading. Meyka AI rates TWST with a grade of B+, reflecting mixed fundamentals in a challenging biotech landscape.

Revenue Beat Signals Demand Strength

Twist Bioscience topped revenue expectations despite ongoing profitability challenges. The company generated $110.72 million in quarterly revenue, surpassing analyst forecasts by $3.08 million.

Strong Sequential Growth

Revenue growth remained positive compared to recent quarters. The latest quarter’s $110.72 million represents solid performance relative to the $103.70 million posted in the prior quarter. This 6.8% sequential increase demonstrates continued customer demand for the company’s synthetic DNA products and services.

Consistent Outperformance Pattern

Twist has now beaten revenue estimates in three of the last four quarters. The company exceeded expectations in May 2025 ($92.79M actual vs $95.39M estimate), August 2025 ($96.06M vs $97.38M), and November 2025 ($99.01M vs $97.40M). This track record suggests strong market adoption of synthetic biology solutions.

Product Portfolio Driving Sales

The company’s diverse revenue streams include synthetic genes, antibody libraries, and DNA data storage solutions. Partnerships with Boehringer Ingelheim and other biotech firms continue supporting revenue expansion. These collaborations validate Twist’s technology platform and expand addressable markets.

EPS Miss Reflects Ongoing Losses

Twist Bioscience’s earnings per share deteriorated significantly, missing expectations by a substantial margin. The company reported -$0.71 per share, falling well short of the -$0.49 estimate.

Widening Loss Per Share

The EPS miss represents a concerning trend. The -$0.71 result is notably worse than the -$0.50 posted in February 2026 and the -$0.44 in November 2025. This marks the worst EPS performance in the last four quarters, indicating margin pressures intensified during the period.

Operating Margin Challenges

Twist’s gross margin stands at 51.6%, which is healthy. However, operating expenses remain elevated relative to revenue. The company’s operating margin sits at -34.4%, reflecting heavy spending on research and development and sales infrastructure. These investments are necessary for growth but continue weighing on profitability.

Path to Profitability Uncertain

With negative free cash flow of -$1.42 per share, Twist faces pressure to demonstrate a clear route to profitability. The company is burning cash to fund operations and growth initiatives. Investors will watch closely for signs of operating leverage and margin expansion in coming quarters.

Stock Reaction and Market Sentiment

Markets responded negatively to Twist’s mixed earnings, sending shares down sharply on the earnings date. The stock declined 6.97% to close at $56.19, reflecting disappointment over the significant EPS miss.

Price Action and Volatility

The stock opened at $59.20 and traded between $56.01 and $59.99 during the session. Trading volume surged to 2.57 million shares, 68% above the 30-day average of 1.53 million. This elevated volume underscores investor interest and concern about the earnings results.

Analyst Consensus Remains Positive

Despite the stock decline, analyst sentiment remains constructive. Nine analysts rate TWST as a buy, with no sell or hold ratings. This suggests the Street believes current weakness presents a buying opportunity for long-term investors in synthetic biology.

Valuation Metrics Under Pressure

The stock trades at a price-to-sales ratio of 9.47x, elevated for an unprofitable company. The price-to-book ratio stands at 8.10x. These multiples reflect investor expectations for future profitability and growth, but the EPS miss raises questions about execution timelines.

Quarterly Performance Trends and Outlook

Examining Twist’s earnings trajectory over the past year reveals a company navigating profitability challenges while maintaining revenue momentum. The pattern suggests both progress and persistent headwinds.

Revenue Trajectory Improving

Revenue has grown from $92.79 million in May 2025 to $110.72 million in May 2026, representing 19.3% year-over-year growth. This acceleration demonstrates strong market demand for synthetic DNA solutions. The company is successfully scaling its customer base and product adoption.

EPS Volatility Concerning

Earnings per share have fluctuated between -$0.44 and -$0.71 over the past four quarters. The latest miss at -$0.71 is the worst result in this period. This volatility suggests operational challenges or one-time charges impacting profitability. Management guidance on cost control will be critical.

Cash Position and Runway

Twist maintains a strong balance sheet with $3.24 per share in cash. The current ratio of 3.78x indicates solid liquidity. However, negative free cash flow means the company is consuming cash reserves. At current burn rates, runway remains adequate, but profitability must improve within 18-24 months.

Final Thoughts

Twist Bioscience beat revenue expectations at $110.72 million, showing strong synthetic DNA demand, but missed on earnings with a -$0.71 EPS. The stock fell 6.97% despite bullish analyst consensus with nine buy ratings and a B+ grade. Investors believe long-term potential justifies current losses, but management must prove a path to profitability and operating leverage. The next two quarters will determine if revenue growth finally converts to positive earnings.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.